Navigation Links
Rifampin: Latent TB treatment saves time money and lives
Date:5/20/2008

ATS 2008, TORONTOA new way to treat patients with latent tuberculosis (TB), who are infected with TB but without symptoms, can effectively treat it in less than half the time and at a lower cost than the current standard treatment, according to researchers who conducted a multi-center, randomized controlled trial. The results will be presented at the American Thoracic Societys 2008 International Conference in Toronto on Tuesday, May 20.

We found that using a therapy of four months of Rifampin instead of the current nine months of Isoniazid costs significantly less for the healthcare system, said lead analyst, Anne Aspler, M.Sc., of the Respiratory Epidemiology & Clinical Research Unit at McGill Universitys Montreal Chest Institute. Overall, Rifampin costs about $484 less per patient treated, which, if we assume that four months of Rifampin has at least equal efficacy to nine months of Isoniazid, represents an added savings to the health system of more than $10,000 per patient prevented from developing TB disease. And because of improvements in compliance, we are actually preventing more cases. This treatment can save money as well as lives.

At present, two billion people are believed to have latent or dormant TB. Of those infected, eight to nine million will develop TB each year, of whom 1.6 million will die. This is one of the most pressing public health crises in our modern world, said Ms. Aspler.

Rifampin is offered in developing countries, where TB presents the greatest burden, at a subsidized cost through the Global Drug Facility of the World Health Organization. In addition to the cost savings, therapy with Rifampin has the advantage of increased compliance.

While Isoniazid therapy is 90 percent effective for those who complete it, in reality, fewer than 50 percent do, Ms. Aspler explained. The high attrition rate can have serious public heath effects, not only for the patients who fail to complete therapy, but also for the individua
'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Page: 1 2

Related medicine news :

1. New chemical can kill latent tuberculosis bacteria
2. New treatment gives hope for pulmonary fibrosis patients
3. Mission Pharmacal Launches Ferralet(R) 90 for Treatment of the Leading Cause of Anemia in the U.S.
4. Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa
5. Mapping of prostate cancer genes opens the door to new treatments
6. Many Diabetics Dont Get Necessary Blood Pressure Treatment
7. MR imaging accurately determines prostate cancer treatment failure
8. Study: Patients 75 years and older with brain tumors may benefit from more aggressive treatment
9. Old antibiotic may find new life as a stroke treatment
10. Radiofrequency ablation is effective treatment for dysplasia in Barretts esophagus
11. New Hair Loss Treatment Proves Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 Members of the Iowa State ... CCIM, Senior Associate of Sales at OutcomesMTM, as their Chairperson. ... to the Board and that his peers chose to keep ... provide the best I can for the citizens of Iowa,” ... positioned to provide a special insight to concerns and issues ...
(Date:7/24/2014)... new study has shown that it is possible to predict ... short-term effects of that same exposure. The findings, which currently ... it possible to develop simpler and cheaper tests to screen ... Despite an overall decrease in incidence of and mortality from ... the disease in their lifetime, and around 20 percent will ...
(Date:7/24/2014)... rare procedure occasionally performed during Jewish circumcisions that involves ... herpes simplex virus type 1 (HSV-1) transmissions documented in ... conducted by Penn Medicine researchers and published online ... Society found. The reviewers, from Penn,s ... in New York, Canada and Israel. , The practiceknown ...
(Date:7/24/2014)... Human Papillomavirus Vaccination (HPV) even after becoming sexually ... results than those who were never vaccinated. These ... Diseases . , Researchers from Boston University ... conducted a cross-sectional study of 235 women age ... HPV status and demographic and behavioral characteristics were ...
(Date:7/24/2014)... July 24, 2014 According to ... Business Models, Technology Roadmap, Forecasts and Analysis - ... is expected to reach $7.7 billion by 2018 ... , Browse 102 market data tables and 30 ... on “3D Mapping Market: Global Advancements, Business Models, ...
Breaking Medicine News(10 mins):Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2Health News:Researchers discover new way to determine cancer risk of chemicals 2Health News:Link between ritual circumcision procedure and herpes infection in infants examined 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 3Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 4
... , , Congressman Chaka Fattah (D-PA) ... America,s healthcare system. , , WASHINGTON, Aug. 17 ... If real reform is to take place it must include a public ... airport in any major city they deliberate how they will get to their ...
... , , CHESTERFIELD, ... RELV ), a nutrition and direct selling company, today launched ... company,s line of proprietary nutritional supplements. , , ... Reliv,s breakthrough r(TM) skincare collection that combines some of the ...
... , , SAN FRANCISCO, ... leader in healthcare data management and decision support solutions ... a strategic alliance with CACTUS Software, a leading provider ... expand the capabilities and simplify the ability of healthcare ...
... , CHICAGO, Aug. 17 Presidential ... furnished two bedroom apartment to the University of Illinois Medical Center ... undergoing care at the medical center. , , ... Towers felt that this was a great way to give back ...
... PARK, N.J., Aug. 17 Managed Health Care Associates, Inc. ... joined MHA as Vice President & General Counsel. In ... all legal matters for the company, including healthcare compliance, contract ... and CFO of MHA commented "The establishment of this important ...
... Volumizing the Brow ... ... eyes change in generally predictable ways: the skin thins and becomes less elastic, brows may ... more prominent. While surgery has long been the accepted standard and offers significant benefits ...
Cached Medicine News:Health News:Reliv International Launches Relivables(TM) Product Family With New Skincare Products and Other Items 2Health News:Reliv International Launches Relivables(TM) Product Family With New Skincare Products and Other Items 3Health News:Quantros and CACTUS Software Establish Strategic Alliance to Provide Customers With Comprehensive Provider Performance Monitoring 2Health News:Quantros and CACTUS Software Establish Strategic Alliance to Provide Customers With Comprehensive Provider Performance Monitoring 3Health News:Presidential Towers Donates Apartment to the University of Illinois Medical Center 2Health News:MHA Announces Gloria Barr, Esq. as Vice President & General Counsel 2Health News:Nonsurgical Technique Can Take Years Off the Appearance of Aging Eyes 2Health News:Nonsurgical Technique Can Take Years Off the Appearance of Aging Eyes 3
(Date:7/24/2014)... MOUNTAIN VIEW, Calif. , July 24, 2014 ... ), a leading provider of medication and supply ... hold a conference call Thursday, July 31, to ... What:  , Omnicell Second Quarter 2014 earnings ... 2014, 1:30 p.m. PTWho:  , Randall Lipps, chairman, ...
(Date:7/24/2014)... (NYSE MKT: IG), a New Jersey based specialty generic drug ... second quarter ended June 30, 2014. Second Quarter ... in the second quarter of 2014, an increase of 70% ... of $13.3 million for the six months ended June 30, ... 2013 , Total revenues generated from the sale of ...
(Date:7/24/2014)... , July 24, 2014 Many new dentists ... can do to ensure that their practice will be a ... the basic supplies they use the most can make all ... many dentists have recently discovered that purchasing discount dental ... According to successful dentists across ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7Dental Supplies Online is Key to Dental Success...Really! 2
... study shows ACTEMRA is first and only biologic to, demonstrate ... ... treatment -, PARIS, June 13 ... -- despite treatment with,current therapies -- achieved significant improvements in signs ...
... France, June 13 , NicOx S.A. (Euronext ... blood pressure data from the 301 phase 3 ... naproxen in,terms of the mean change from baseline ... (p<0.05 for 3 out of 4 comparisons). Commonly ...
Cached Medicine Technology:ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 2ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 3ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 4ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 5ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 6ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 7NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR 2NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR 3NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: